>. . . Important points from this report include: >- A seven-year-old experienced a stroke. - One child and one infant suffered facial paralysis. - One infant had a kidney adverse event, either kidney injury or failure. - Of the 34 adverse event cases, 24 (71%) were classified as serious. - Predominantly female patients were affected — at least 25 of 34 (73.5%) patients. - Table 6 reports 34 cases of use in pediatric individuals. However, 28 additional cases were excluded because details such as height and weight were “not consistent with pediatric subjects.” - Ages ranged from two months to nine years, with median 4.0 years, which means half the children were under four years of age. - 132 adverse events were reported in the 34 children – i.e., an average of 3.88 AEs per child. >Shockingly, Pfizer concluded: >>“No new significant safety information was identified based on a review of these cases compared with the non-paediatric population.” >Please read the disturbing, two-page report by the Post-Marketing Group (Team 1) below. . .